Metelimumab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | TGF beta 1 |
| Clinical data | |
| ATC code | none |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number |
272780-74-2  |
| ChemSpider | none |
 (what is this?) (verify) | |
Metelimumab (CAT-192) is a human IgG4 monoclonal antibody that neutralizes TGF beta 1 which had been chosen for further development for the treatment of diffuse cutaneous systemic sclerosis, also known as scleroderma. Touted as a drug of the future,[1] metelimumab was dropped from further development in favour of fresolimumab,[2] which is currently being developed by Genzyme.[3]
History
Metelimumab was isolated by Cambridge Antibody Technology (CAT) using its phage display technology. In 2000, CAT signed a collaborative deal with Genzyme to further develop TGF beta antibodies.[4][5]
In 2004, CAT and Genzyme revealed that Phase I/II trials of metelimumab for scleroderma showed this antibody to be safe and well tolerated across all dose levels, although no conclusions regarding efficacy of the compound could be made.[6]
Initial trials targeted the skin condition scleroderma[7] but, after some unsuccessful clinical trial results, the product was dropped in favour of fresolimumab,[2] which is currently being developed by Genzyme.[3]
References
- ↑ http://journals.prous.com/journals/servlet/xmlxsl/pk_journals.xml_summary_pr?p_JournalId=2&p_RefId=860002&p_IsPs=N
- 1 2 http://www.independent.co.uk/news/business/news/cat-may-abandon-skin-drug-after-trial-results-disappoint-569445.html
- 1 2 http://www.genzymeoncology.com/onc/research/onc_p_research.asp
- ↑ http://prnwire.com/cgi-bin/stories.pl?ACCT=104&STORY=/www/story/09-28-2000/0001324438&EDATE=
- ↑ http://www.drugdiscoveryonline.com/article.mvc/Cambridge-Antibody-Genzyme-to-collaborate-on-0001?VNETCOOKIE=NO
- ↑ http://goliath.ecnext.com/coms2/gi_0199-693661/CAT-192-is-safe-but.html
- ↑ http://www.genzymeoncology.com/onc/clinical/trialdetailresults.asp?nct=NCT00043706